Results 121 to 130 of about 115,651 (262)
Heavy Drinking, Alcohol Use Disorder, and Obesity. [PDF]
Shuey B +6 more
europepmc +1 more source
Abstract Background and aims Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited.
Javad Heshmati +6 more
wiley +1 more source
Evaluating acute and post-acute COVID-19 symptoms among patients with and without alcohol-related cirrhosis: implications for quality management. [PDF]
Dasarathy D +11 more
europepmc +1 more source
‘I'd rather have worse gums than worse lungs’: Young people's views of nicotine pouches in the UK
Abstract Background and aims Nicotine pouches entered the UK market in 2019. Although research has shown that young people's prevalence of use has been low, it has been reported to be increasing and a cause for concern. This paper reports the findings of the first qualitative study in the UK to explore the views of 14–16 year olds' knowledge, awareness
Andy MacGregor +7 more
wiley +1 more source
This is my way of Drinking: A Scoping Review of how Individuals Narrate Their Alcohol-Related Problems. [PDF]
Christiansen R +4 more
europepmc +1 more source
Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley +1 more source
Abstract Background and aims Oral nicotine pouches (ONPs) have seen a dramatic rise in sales since their introduction to the US market in 2016. We aimed to define the relationship between ONP prices and sales (e.g. price elasticity of demand) and determine how taxes on cigarettes and e‐cigarettes (ECs) impact ONP sales.
Yanyun He +7 more
wiley +1 more source
Aberrant cortico-striato-limbic functional connectivity to alcohol cues in co-occurring bipolar disorder and alcohol use disorder. [PDF]
Mellick WH +3 more
europepmc +1 more source
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden +10 more
wiley +1 more source
Harmful alcohol use and associated factors among patients with neuropsychiatric disorders in Ethiopia: a systematic review and meta-analysis. [PDF]
Tassew WC +7 more
europepmc +1 more source

